Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- T-cell NHL (PTCL or CTCL)
- Main trialPhase 1
- “The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).”In the company’s words, NCT07192471 on ClinicalTrials.gov
Other drugs for T-cell NHL (PTCL or CTCL)
- PTX-100Prescient Therapeutics, Ltd. · Phase 2
- MDSY-1240Medsyn Biopharma, LLC · Phase 1/2
- VG712Virogen Biotechnology Inc. · Phase 2
- GolcadomideCelgene · Phase 1/2
- Purinostat MesylateChengdu Zenitar Biomedical Technology Co., Ltd · Phase 2
- FenretinideSciTech Development, Inc. · Phase 1
Coming up1
- Mar 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Mar 2029 | A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026